Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2000
12/28/2000WO2000078927A2 Spheroid preparation
12/28/2000WO2000078815A1 ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE
12/28/2000WO2000078806A1 Mage-a1 peptides presented by hla class ii molecules
12/28/2000WO2000078803A2 Use of eif4e binding agents in therapy
12/28/2000WO2000078802A2 Secreted polypeptides and corresponding polynucleotides
12/28/2000WO2000078750A1 New pharmaceutically active compounds
12/28/2000WO2000078738A1 Melamine derivatives as potent anti-cancer agents
12/28/2000WO2000078736A1 1,4-diazacycloheptane derivatives as neuroprotective agents
12/28/2000WO2000078735A1 Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
12/28/2000WO2000078731A1 5-cyano-2-aminopyrimidine derivatives
12/28/2000WO2000078355A2 Biologically active materials
12/28/2000WO2000078348A1 Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
12/28/2000WO2000078347A1 Cell growth inhibition
12/28/2000WO2000078341A1 A method for the prophylaxis and/or treatment of medical disorders
12/28/2000WO2000078327A2 Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication
12/28/2000WO2000078317A1 Integrin receptor antagonists
12/28/2000WO2000078313A1 Arylthiazolidinedione and aryloxazolidinedione derivatives
12/28/2000WO2000078266A2 Interferon tau mutants and methods for making them
12/28/2000WO2000078247A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
12/28/2000WO2000078143A1 Method of increasing the content of flavonoids and phenolic substances in plants
12/28/2000WO2000063348A3 Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof
12/28/2000WO2000061551A3 Pyrimidine-2-one derivatives as integrin receptor ligands
12/28/2000WO2000058460A3 Casb619 involved in colon cancers
12/28/2000WO2000055162A3 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
12/28/2000WO2000050051A3 Reovirus for the treatment of cellular proliferative disorders
12/28/2000WO2000049021A3 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
12/28/2000WO2000048614A3 Method for producing anti-tumor th1 cells
12/28/2000WO2000047584A3 Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
12/28/2000WO2000045851A3 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
12/28/2000WO2000045845A3 Liposome composition and method for administration of a radiosensitizer
12/28/2000WO2000043495A3 33 human secreted proteins
12/28/2000WO2000043373A3 Kinase inhibitors
12/28/2000WO2000037640A3 Compositions and methods for the treatment of tumor
12/28/2000WO2000034474A3 Growth factor homolog zvegf3
12/28/2000WO2000032776A3 Secreted amd transmembrane polypeptides and nucleic acids encoding the same
12/28/2000WO2000031093A3 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
12/28/2000WO1999052493A3 Compounds that inhibit the binding of integrins to their receptors
12/28/2000DE19929715A1 New 11-beta-long chain substituted estratriene derivatives, are antiestrogens or tissue-selective partial estrogens useful e.g. for treating hormone-dependent cancer or osteoporosis
12/28/2000DE19929569A1 Composition for treating malignant disease, comprising E1A-defective adenovirus that can replicate in presence of YB-1 protein
12/28/2000DE19929410A1 New octapepide compounds as alpha v beta 6 integrin inhibitors useful for treating and diagnosing heart disease, tumors, osteoporosis, fibrosis, inflammation, infection and psoriasis
12/28/2000DE19928342A1 New vector for tissue-specific expression, useful for treating tumors, contains gene for e.g. a cytotoxin under control of tissue-specific promoter and enhancer
12/28/2000CA2382425A1 Interferon tau mutants and methods for making them
12/28/2000CA2377263A1 Polynucleotides and polypeptides encoded thereby
12/28/2000CA2377246A1 Arylthiazolidinedione and aryloxazolidinedione derivatives
12/28/2000CA2376284A1 A method for the prophylaxis and/or treatment of medical disorders
12/28/2000CA2376077A1 Integrin receptor antagonists
12/28/2000CA2375508A1 Methods and products for manipulating uncoupling protein expression
12/28/2000CA2375498A1 Epithelial cell growth inhibitors
12/28/2000CA2375493A1 Human transport proteins
12/28/2000CA2375414A1 Human transcriptional regulator proteins
12/28/2000CA2375407A1 Rna metabolism proteins
12/28/2000CA2375312A1 Melamine derivatives as potent anti-cancer agents
12/28/2000CA2375236A1 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
12/28/2000CA2375182A1 5-cyano-2-aminopyrimidine derivatives
12/28/2000CA2374548A1 Biologically active materials
12/28/2000CA2373391A1 Spheroid preparation
12/28/2000CA2371924A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
12/28/2000CA2340319A1 Method for producing plants with increased flavonoid and phenolic compound content
12/27/2000EP1063293A2 Transforming growth factor alpha H1
12/27/2000EP1063234A2 Hydrophobic taxane derivates
12/27/2000EP1062514A2 C-myc coding region determinant-binding protein (crd-bp)
12/27/2000EP1062363A1 Method for producing agents for treating tumour diseases and for immunosuppression
12/27/2000EP1062348A1 Recombinant onconase, and chemical conjugates and fusion proteins of recombinant onconase
12/27/2000EP1062336A1 Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
12/27/2000EP1062331A1 Compounds related to pap-1
12/27/2000EP1062328A1 Suicide gene therapy system for the treatment of brain tumours
12/27/2000EP1062239A2 Ribonucleotide polypeptides containing metal
12/27/2000EP1062236A1 31 human secreted proteins
12/27/2000EP1062232A2 Molecules that home to various selected organs or tissues
12/27/2000EP1062229A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/27/2000EP1062228A1 Plasminogen-related gene b polypeptides
12/27/2000EP1062222A1 Serine peptidase modulators
12/27/2000EP1062218A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
12/27/2000EP1062216A1 Inhibitors of phospholipase a2
12/27/2000EP1062215A1 Antagonists of gonadotropin releasing hormone
12/27/2000EP1062214A1 Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce tnfa levels
12/27/2000EP1062210A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
12/27/2000EP1062209A1 Metabolically inert anti-inflammatory and anti-tumor antifolates
12/27/2000EP1062207A1 9-aminoacridine derivatives and process for the preparation thereof
12/27/2000EP1062204A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1062202A1 Cytostatic agents
12/27/2000EP1062199A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1061958A2 Radioactive seed implants
12/27/2000EP1061944A2 Therapeutic chemokine receptor antagonists
12/27/2000EP1061938A1 Oral compositions at low dosage of cytotoxic proteins
12/27/2000EP1061937A1 Improved radiation therapy methods
12/27/2000EP1061921A1 Vitronectin receptor antagonists
12/27/2000EP1061916A2 Use os nitrone compounds for the inhibition of angiogenesis
12/27/2000EP1061915A1 Pharmaceutical formulations of taxanes
12/27/2000EP1061912A1 Phenanthrofuran derivatives
12/27/2000EP1061907A1 Monoterpenoid derivatives for treatment of cancer
12/27/2000EP1061903A1 Delivery system to modulate immune response
12/27/2000EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same
12/27/2000EP1061805A1 Regulation of endogenous gene expression in cells using zinc finger proteins
12/27/2000EP0823900B1 Quinazoline derivatives
12/27/2000EP0821671B1 Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
12/27/2000EP0821666B1 Derivatives of succinamide and their use as metalloproteinase inhibitors
12/27/2000EP0804483B1 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
12/27/2000EP0671909B1 Syndecan stimulation of cellular differentiation
12/27/2000EP0619730B1 Composition of antineoplastic agents incorporated in micelles
1 ... 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 ... 2211